Drug delivery company Avecho has announced positive results from its Phase 2a studying its topical cannabinoid gel for the management of pain associated with osteoarthritis of the hand.
The study dosed patients over a four-week period, with the study demonstrating statistically significant daily improvements in hand pain, hand functionality, grip strength, finger stiffness and anxiety.
Hand osteoarthritis is a common, painful, progressive and irreversible condition that significantly impairs hand movement.
The study was run by Dr Daniel Lewis of the Daniel Lewis Rheumatology Centre and Professor Ian McGregor from research group the Lambert Initiative
Dr Lewis said: “There is an unmet need for effective treatment in this condition which has a significant impact on the quality of life.
“We are very encouraged by these results which will need to be confirmed with a longer placebo-controlled trial in a larger number of patients.”
Cannabinoids are lipid soluble molecules with poor oral bioavailability.
Avecho is focused on seeking Therapeutic Goods Administration for its oral cannabinoid capsule, as well as trailing transdermal drug delivery to increase their absorption.
Subscribe to our free @AuManufacturing newsletter here.